A new hormone inhibitor appetite was discovered

According to RCO News AgencyA completely new candidate has been found for the treatment of weight loss, and scientists have first discovered how the hormone produced by hypothalamus during sleep has a direct impact on adjustment of appetite and metabolism. This is the first time a hormone called raptin has been associated with sleep and obesity.

According to New Atlantic, the discovery opens the way for the development of a new category of drugs that can cope with obesity like GLP-1 agonists.

Chinese scientists said in the study: Sleep lack of sleep is related to obesity, but the mechanisms of this relationship are still unclear. In this study, we identified a hippotalamus protein hormone in humans and mice that suppresses obesity. This hormone is separated from the Reticulocal-1 (RCN۲) and we have named it raptin.

Researchers at Xiangya Hospital (Xiangya) are the first to identify and understand how this hypothalamic hormone gives the intestine a satiety signal and restricts food intake.

In addition, poor or inadequate sleep greatly reduces the rappin level, which blocks appetite control and the raptin level is much lower in obese people.

Researchers say: Reptin is attached to the metabotropic glutamate (GRM3) receptor in hypothalamic and stomach neurons to prevent appetite and gastric emptying, respectively.

Reptin is a cut of reticulocalucleechel-1 protein (RCN۲) that plays an important role in bone and cancer formation, but has never been associated with appetite control or other metabolic functions.

In this study, the researchers identified and confirmed the role of ripin in metabolic processes through a combination of proteomix to understand the structure and biology of RCN2 protein, as well as molecular biology, neuroscience and human clinical data. The role of Reptin was constant in both mice and in humans.

Basically, Raptin is closely linked to round -the -clock rhythm cycles, and while scientists have not stated at what particular stage of the hormone produced and secreted, its surfaces reach their peak during the night and closure of the eye. This hormone is likely to be produced and secreted during the rapid motion of the eye, nrem.

The level of this hormone gradually decreases during the day before it goes up again in the next sleep cycle. However, further studies need to confirm whether the sleeping stages play a particular role here.

Poor or inadequate sleep plays a role in weight gain associated with this hormone. One of these studies in year 4 showed that sleep deficiency increases ghrelin production, which results in an increase in appetite and limits the secretion of leptin hormone (Leptin), which then interferes with intestinal satiety signals. Other research has been associated with poor sleep with the increase in stress hormones and their effect on metabolic regulation.

In humans, researchers evaluated the raptine levels, sleep quality and other metabolic criteria in four participants, of whom were clinically obese. They then performed a test with 4 people, with 2 in the control group and 3 people for three months with sleep limit (SRT). At the end of the trial, the data was collected to evaluate changes in raptin levels and body weight as well as sleep quality and energy intake.

Researchers say: Participants who suffer from sleep deficiency have lower raptin levels and exacerbate obesity, while patients with obesity under SRT had higher raptin levels and reduced obesity phenotypes. These findings emphasize the importance of sleep quality on metabolism.

In addition, a genetic study of four obese individuals led to the discovery of a type of RCN۲, which was found in the biological code of a group of members of a family who all suffered from NESS syndrome (NES). NES treatment is currently difficult and generally considered as a mental disorder and is often misinterpreted. So these findings can have a huge impact on those who suffer from these nighttime overeating. These people prevented the production of raptin, all of which were obese.

The team also pointed to the relationship between high -fat diets and insomnia, and said more research was needed to see how it could affect the production of raptin and its ability to adjust appetite. In general, however, these findings provide the basis for developing new therapies for weight loss and obesity treatment.

The researchers said: “Here we showed that the release of the raptine of the hypothalamus reduces appetite, but does not affect other important round -the -clock behaviors, including the sleep cycle itself or physical activity. The study identifies us as a unique hypothalamic hormone that collaborates with GRM1 to suppress appetite and obesity, thus providing a new potential way to treat obesity.

This study is published in the journal Cell Research.

The end of the message